|
|
Volumn 11, Issue 6, 2004, Pages 417-421
|
|
The coxib conundrum: lessons from the rise and fall of rofecoxib.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
LACTONE;
PROSTAGLANDIN SYNTHASE INHIBITOR;
ROFECOXIB;
SULFONE;
ANIMAL;
BLOOD PRESSURE;
CARDIOVASCULAR DISEASE;
CHEMICALLY INDUCED DISORDER;
CLINICAL TRIAL;
COHORT ANALYSIS;
CONTROLLED CLINICAL TRIAL;
DRUG CONTROL;
DRUG EFFECT;
DRUG INDUSTRY;
EDITORIAL;
ETHICS;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
LEGAL ASPECT;
PEPTIC ULCER;
POSTMARKETING SURVEILLANCE;
RANDOMIZED CONTROLLED TRIAL;
UNITED STATES;
ANIMALS;
BLOOD PRESSURE;
CARDIOVASCULAR DISEASES;
COHORT STUDIES;
CYCLOOXYGENASE INHIBITORS;
DRUG AND NARCOTIC CONTROL;
DRUG INDUSTRY;
HUMANS;
LACTONES;
PEPTIC ULCER;
PRODUCT SURVEILLANCE, POSTMARKETING;
RANDOMIZED CONTROLLED TRIALS;
SULFONES;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 16644388324
PISSN: 10752765
EISSN: None
Source Type: Journal
DOI: 10.1097/01.mjt.0000149719.58535.b0 Document Type: Editorial |
|
Times cited : (9)
|
|
References (0)
|
